Out-Licensing
In association with the Viridian merger, miRagen’s business strategy transitioned to prioritizing VRDN-001 for the development of thyroid eye disease and away from its legacy programs that modulate microRNAs. The presentations and publications listed below provide data on the microRNA programs that are now available for out-licensing, spin out or sale. For further information please contact Outlicensing@viridiantherapeutics.com.
- September 29, 2020 [VIDEO] – Next Generation miR-29 Mimic as a Therapy for Pulmonary Fibrosis OTS 2020
- September 29, 2020 Next Generation miR-29 Mimic as a Therapy for Pulmonary Fibrosis OTS 2020
- February 1, 2020 Clinical Development of microRNA Inhibitors 2020 T-cell Lymphoma Forum – Industry Innovations Talk
- January 30, 2020 Phase I Trial of Cobomarsen, a MiR-155 Inhibitor, in Patients with Aggressive HTLV-1 Associated ATLL: Disease Stabilization and Biomarker Analysis ATLL T-Cell Forum 2020
- October 28, 2019 Targeted Delivery of miR-29 Mimics for Fibrotic Indications Oligonucleotide-Based Therapeutics Conference
- October 28, 2019 Clinical Development of microRNA Inhibitors Oligonucleotide-Based Therapeutics Conference
- October 16, 2019 Development of MRG-110, an LNA-AntimiR Targeting miR-92a for Use in Tissue Repair and Regeneration OTS, October 2019
- October 7, 2019 SOLAR: A Phase 2, Global, Randomized, Active Comparator Study to Investigate the Efficacy and Safety of Cobomarsen in Subjects with Mycosis Fungoides (MF) EORTC miRagen Breakfast Symposium
- October 7, 2019 Cobomarsen as a Therapy for Mycosis Fungoides microRNA Therapeutics in Mycosis Fungoides and ATLL
- August 29, 2019 Next Generation miR-29 Mimics as a Therapy for Pulmonary Fibrosis IPF Summit 2019